Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3124084 | 0.83 | PNMT (0.56) | PNMTMEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL3124097 | 0.82 | PNMT (0.62) | PNMTMEN1KMT2A | |
| SCHEMBL3129933 | 0.82 | PNMT (0.55) | PNMTMEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL3130633 | 0.82 | PNMT (0.55) | PNMTMEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL13083684 | 0.79 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL14997331 | 0.77 | PNMT (0.56) | PNMTMEN1KMT2AADRA2AADRA2B | |
| SCHEMBL3125553 | 0.77 | PNMT (0.55) | PNMTMEN1KMT2ACXCR4 | |
| SCHEMBL3119353 | 0.74 | PNMT (0.60) | PNMTMEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL3128091 | 0.74 | PNMT (0.60) | PNMTMEN1KMT2ACXCR4 | |
| SCHEMBL3127929 | 0.74 | PNMT (0.56) | PNMTOPRM1OPRL1KCNH2CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2143714-B1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA CO (JP) | 2013-06-05 | — | — | EP | disclosed |
| EP-2143714-B1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA CO (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-8273766-B2 | Tetrahydroisoquinoline compound | KOWA COMPANY, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273766-B2 | Tetrahydroisoquinoline compound | KOWA COMPANY, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273766-B2 | Tetrahydroisoquinoline compound | KOWA COMPANY, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2143714-A1 | TETRAHYDROISOQUINOLINE COMPOUND | Kowa Company, Ltd. (JP) | 2010-01-13 | — | — | EP | disclosed |
| EP-2143714-A1 | TETRAHYDROISOQUINOLINE COMPOUND | Kowa Company, Ltd. (JP) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | CCR3, CCR5, CCR1 | PNMT 1739/4885MEN1 2946/4885KMT2A 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.